Advertisement

Cell Line Engineering for Production of Therapeutic Antibody Glycoforms with Increased Biological Activity

  • Pablo Umana
  • Peter Bruenker
  • Claudia Ferrara
  • Samuel Moser
  • Tobias Suter
  • Christian Gerdes
  • Ursula Puentener
  • Joel Jean-Mairet
  • Patrick Buholzer
  • Manuel Spaeni
Part of the ESACT Proceedings book series (ESACT, volume 2)

Keywords

Trast Uzumab Immune Effector Cell Animal Cell Technology Core Fucose Solid Breast Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J. Lab. Clin. Med. (1999) 134: 445.Google Scholar
  2. 2.
    Nat. Med. (2000) 6: 443.Google Scholar
  3. 3.
    P.N.A.S. USA (2000) 97: 7503.Google Scholar
  4. 4.
    Blood (2002) 99: 754.Google Scholar
  5. 5.
    Glycobiology (1995) 5: 813.Google Scholar
  6. 6.
    Nat. Biotechnol. (1999) 17: 176.Google Scholar
  7. 7.
    J. Biol. Chem. (2002) 277: 26733.Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Pablo Umana
    • 1
  • Peter Bruenker
    • 1
  • Claudia Ferrara
    • 1
  • Samuel Moser
    • 1
  • Tobias Suter
    • 1
  • Christian Gerdes
    • 1
  • Ursula Puentener
    • 1
  • Joel Jean-Mairet
    • 1
  • Patrick Buholzer
    • 1
  • Manuel Spaeni
    • 1
  1. 1.GLYCART BiotechnologyZurichSwitzerland

Personalised recommendations